Cutia Therapeutics (HKG:2487)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Developing Innovative and Comprehensive Solutions	336.15M	279.62M	137.62M	11.37M	2.04M
Developing Innovative and Comprehensive Solutions Growth	20.22%	103.17%	1110.83%	457.70%	-
Total	336.15M	279.62M	137.62M	11.37M	2.04M
Total Growth	20.22%	103.17%	1110.83%	457.70%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
People’s Republic of China (PRC)	336.15M	279.62M	137.62M	11.37M	2.04M
People’s Republic of China (PRC) Growth	20.22%	103.17%	1110.83%	457.70%	-
Total	336.15M	279.62M	137.62M	11.37M	2.04M
Total Growth	20.22%	103.17%	1110.83%	457.70%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 15, 2026

Data Sources Report a data error